SG11201908384XA - Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas - Google Patents

Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Info

Publication number
SG11201908384XA
SG11201908384XA SG11201908384XA SG11201908384XA SG 11201908384X A SG11201908384X A SG 11201908384XA SG 11201908384X A SG11201908384X A SG 11201908384XA SG 11201908384X A SG11201908384X A SG 11201908384XA
Authority
SG
Singapore
Prior art keywords
international
anchor
linker
cells
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Scott Dessain
Rama Puligedda
Original Assignee
Lankenau Inst Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lankenau Inst Medical Res filed Critical Lankenau Inst Medical Res
Publication of SG11201908384XA publication Critical patent/SG11201908384XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11201908384X 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas SG11201908384XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762476599P 2017-03-24 2017-03-24
US201762526608P 2017-06-29 2017-06-29
PCT/US2018/024073 WO2018175917A1 (en) 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Publications (1)

Publication Number Publication Date
SG11201908384XA true SG11201908384XA (en) 2019-10-30

Family

ID=63584730

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201908384X SG11201908384XA (en) 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
SG10202110530WA SG10202110530WA (en) 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202110530WA SG10202110530WA (en) 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Country Status (7)

Country Link
US (2) US11946074B2 (cg-RX-API-DMAC7.html)
EP (1) EP3601558A4 (cg-RX-API-DMAC7.html)
JP (1) JP7287940B2 (cg-RX-API-DMAC7.html)
CA (1) CA3056249A1 (cg-RX-API-DMAC7.html)
IL (2) IL312457A (cg-RX-API-DMAC7.html)
SG (2) SG11201908384XA (cg-RX-API-DMAC7.html)
WO (1) WO2018175917A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7287940B2 (ja) * 2017-03-24 2023-06-06 ランケナウ・インスティテュート・フォー・メディカル・リサーチ ハイブリドーマによって分泌されるモノクローナル免疫グロブリンの誘導性細胞外膜捕捉のための方法及び組成物
CA3130051A1 (en) * 2019-02-18 2020-08-27 Nb Health Laboratory Co., Ltd. Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376170B1 (en) * 1994-10-03 2002-04-23 The Scripps Research Institute Ligand capture-directed selection of antibody
DE19900635A1 (de) 1999-01-11 2000-07-13 Deutsches Krebsforsch Selektion von monoklonalen Antikörpern
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
DE60238308D1 (de) 2001-02-20 2010-12-30 Univ Georgia Schnellproduktion monoklonaler antikörper
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US8557575B2 (en) 2008-01-28 2013-10-15 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
CN102245771B (zh) 2008-12-16 2013-04-10 诺瓦提斯公司 酵母展示系统
KR20120117931A (ko) 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
EP2390661B1 (en) * 2010-05-02 2015-06-24 Miltenyi Biotec GmbH An anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell
TWI864338B (zh) 2012-11-14 2024-12-01 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI619727B (zh) 2013-02-27 2018-04-01 中央研究院 抗體之原位親和力成熟作用
TWI588259B (zh) 2015-03-06 2017-06-21 Methods for screening antigen-specific fusion tumor cells
JP7287940B2 (ja) * 2017-03-24 2023-06-06 ランケナウ・インスティテュート・フォー・メディカル・リサーチ ハイブリドーマによって分泌されるモノクローナル免疫グロブリンの誘導性細胞外膜捕捉のための方法及び組成物

Also Published As

Publication number Publication date
WO2018175917A1 (en) 2018-09-27
US11946074B2 (en) 2024-04-02
JP2020515288A (ja) 2020-05-28
CA3056249A1 (en) 2018-09-27
US20200010810A1 (en) 2020-01-09
EP3601558A1 (en) 2020-02-05
JP7287940B2 (ja) 2023-06-06
IL269472B1 (en) 2024-06-01
EP3601558A4 (en) 2021-01-06
US20240191207A1 (en) 2024-06-13
IL269472B2 (en) 2024-10-01
IL312457A (en) 2024-06-01
SG10202110530WA (en) 2021-11-29
IL269472A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201906341XA (en) Improved serum albumin binders
SG11201906264YA (en) Improved serum albumin binders
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201909499QA (en) Humanized antigen-binding domains against cd19 and methods of use
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201407644UA (en) Methods for making fully human bispecific antibodies using a common light chain
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201903693QA (en) Polypeptide variants and uses thereof
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201907754RA (en) Anti-phf-tau antibodies and uses thereof
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201811015RA (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof